

Bibliografía

- Al, M. y Van Hout, B. (2000). Bayesian approach to economic analysis of clinical trials: The case of Stenting versus Balloon Angioplasty. *Health Economics*, **9**: 599–609.
- Albert, C. y Chib, S. (1993). Bayesian analysis of binary and polychotomus response data. *Journal of the American Statistical Association*, **88**: 669–679.
- Albi, E. (1989). *Introducción al Análisis Coste–Beneficio*. Instituto de Estudios Fiscales, Madrid.
- Alonso, J., Prieto, L. y Anto, J. (1994). The Spanish version of the Nottingham health profile: A review of adaptation and instrument characteristics. *Quality of Life Research*, **3**: 385–393.
- Altman, D. (1985). Comparability of randomised groups. *Statistician*, **34**: 125–136.
- Anand, S. y Hanson, K. (1997). Disability–adjusted life years: A critical review. *Journal of Health Economics*, **16**: 695–702.
- Arnold, B., Castillo, E. y Sarabia, J. (1998). Bayesian analysis for classical distributions using conditionally specified priors. *Sankhya–The Indian Journal of Statistics*, **60**: 228–245.

- Arnold, B., Castillo, E. y Sarabia, J. (2001a). Bayesian inference using conditionally specified priors. *Handbook of Applied Econometrics and Statistical Inference*. Marcel Dekker, New York.
- Arnold, B., Castillo, E. y Sarabia, J. (2001b). Conditionally specified distributions: An introduction. *Statistical Science*, **16**: 249–274.
- Arnold, B., Castillo, E., Sarabia, J. y González-Vega, L. (2000). Multiple modes in densities with normal conditionals. *Statistics and Probability Letters*, **49**: 355–363.
- Badía, X., Roset, M., Montserrat, S., Herdman, M. y Segura, S. (1999). La versión Española del EuroQol: Descripción y aplicaciones. *Medicina Clínica*, **112**: 79–86.
- Bang, H. y Tsiatis, A. (2000). Estimating medical costs with censored data. *Biometrika*, **87**: 329–343.
- Barber, J. y Thompson, S. (2003). Multiple regression of cost data: Use of generalised linear models. *Journal of Health Services Research & Policy*, en prensa.
- Bassi, C., Larvin, M. y Villatoro, E. (2003). Antibiotic therapy for Prophylaxis against infection of Pancreatic Necrosis in acute Pancreatitis. *Cochrane Database System Review*, **4**.
- Berry, D. (1996). *Statistics: A Bayesian Perspective*. Duxbury Press, Belmont.
- Birch, S. y Gafni, A. (1992). Cost–Effectiveness/Utility analysis. Do current decision rules lead us to where we want to be? *Journal of Health Economics*, **11**: 270–296.

- Bjønner, J. y Keiding, H. (2004). Cost-effectiveness with multiple outcomes. *Health Economics*, en prensa.
- Box, G. y Tiao, G. (1973). *Bayesian Inference in Statistical Analysis*. Addison-Wesley, Reading, MA.
- Bradford, W., Kleit, A., Krousel-Wood, M. y Re, R. (2001). Stochastic frontier estimation of cost models within the hospital. *The Review of Economics and Statistics*, **83**: 302–309.
- Briggs, A. (1999). Bayesian approach to stochastic cost-effectiveness analysis. *Health Economics*, **8**: 257–261.
- Briggs, A. (2000). Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics*, **17**: 479–500.
- Briggs, A. (2001). Handling uncertainty in economic evaluation and presenting the results. M. Drummond y A. McGuire, eds., *Economic Evaluation in Health Care. Merging Theory with Practice*, pp. 172–214. Oxford University Press, New York.
- Briggs, A. y Fenn, P. (1998). Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. *Health Economics*, **7**: 723–740.
- Briggs, A. y Gray, A. (1999). Handling uncertainty when performing economic evaluation of health care interventions. *Health Technology Assessment*, **3**: 1–134.
- Briggs, A., Wonderling, D. y Mooney, C. (1997). Pulling cost-effectiveness analysis up by its bootstraps: A non-parametric approach to confidence interval estimation. *Health Economics*, **6**: 327–340.

- Brooks, R. y el grupo EuroQol (1996). EuroQol: The current state of play. *Health Policy*, **37**: 53–72.
- Brophy, J. y Joseph, L. (1995). Placing trials in context using Bayesian analysis: Gusto revisited by Reverend Bayes. *Journal of the American Medical Association*, **23**: 871–875.
- Brouwer, W., Rutten, F. y Koopmanschap, M. (2001). Costing in economic evaluations. M. Drummond y A. McGuire, eds., *Economic Evaluation in Health Care. Merging Theory with Practice*, pp. 69–93. Oxford University Press, New York.
- Canadian Coordinating Office of Health Technology Assessment (1997). *Guidelines for Economic Evaluation of Pharmaceuticals: Canada*. CCOHTA, Ottawa.
- Carey, K. (2000). A multilevel modelling approach to analysis of patient costs under managed care. *Health Economics*, **9**: 435–446.
- Carides, G., Heyse, J. y Iglewicz, B. (2000). A regression-based method for estimating mean treatment cost in the presence of right-censoring. *Biostatistics*, **1**: 229–313.
- Carlin, B. y Polson, N. (1992). Monte Carlo Bayesian methods for discrete regression models and categorical time series. *Bayesian Statistics*, **4**: 577–586.
- Castillo, E. y Galambos, J. (1989). Conditional distributions and the bivariate normal distribution. *Metrika*, **36**: 209–214.
- Chaloner, K. (1995). The elicitation of prior distributions. D. Berry y D. Stangl, eds., *Case Studies in Bayesian Biostatistics*, pp. 141–156. Marcel Dekker, New York.

- Chaloner, K. (1996). Elicitation of priors distributions. D. Berry y D. Stangl, eds., *Bayesian biostatistics*. Marcel Dekker, New York.
- Chaloner, K. y Duncan, G. (1983). Assessment of a Beta prior distribution: PM Elicitation. *The Statistician*, **32**: 174–180.
- Chaloner, K. y Rhome, F. (2001). Quantifying and Documenting Prior Beliefs in Clinical Trials. *Statistics in Medicine*, **20**: 581–600.
- Chaudhary, M. y Stearns, S. (1996). Estimating confidence intervals for cost–effectiveness ratios: An example from a randomized trial. *Statistics in Medicine*, **15**: 1447–1458.
- Cox, D. (1971). *The Analysis of Binary Data*. Methuen, London.
- Coyle, D. y Drummond, M. (1998). Analyzing differences in the costs of treatment across centres within economic evaluations. *International Journal of Technology Assessment in Health Care*, **17**: 155–163.
- Craig, B. y Tseng, D. (2002). Cost–effectiveness of Gastric Bypass for severe obesity. *American Journal of Internal Medicine*, **113**: 491–498.
- Deeks, J. (1998). Odds ratios should be used only in case–control studies and logistic regression analysis. *British Medical Journal*, **317**: 1155.
- Desky, S. y Naglie, G. (1990). A clinician’s guide to cost–effectiveness analysis. *Annals of Internal Medicine*, **113**: 147–154.
- Doubilet, P., Begg, C., Weinstein, M., Braun, P. y McNeil, B. (1985). Probabilistic sensitivity analysis using Monte Carlo simulation: A practical approach. *Medical Decision Making*, **5**: 157–177.
- Drummond, M., Stoddart, G. y Torrance, G. (1987). *Methods for the Economic Evaluation of Health Care Programmes*. Oxford University Press, Oxford.

- Eddy, D., Hasselblad, V. y Schachter, R. (1992). *Meta-analysis by the Confidence Profile Method: The Stastical Synthesis of Evidence*. Academic Press, Boston.
- Efron, B. y Tibshirani, R. (1993). *An Introduction to the Bootstrap*. Chapman and Hall, New York.
- Eisenberg, J. (1989). Clinical economics: A guide to economic analysis of clinical practice. *Journal of the American Medical Association*, **262**: 2879–2886.
- Feller, W. (1968). *An Introduction to Probability Theory and its Applications, Volume 1, 3rd edition*. Willey, New York.
- Fenwick, E., Claxton, K. y Sculpher, M. (2001). Representing uncertainty: The role of cost-effectiveness acceptability curves. *Health Economics*, **10**: 779–787.
- Fenwick, E., O'Brien, B. y Briggs, A. (2004). Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions. *Health Economics*, **13**: 405–415.
- Fernández, C., Ley, E. y Steel, M. (2001a). Benchmark priors for Bayesian model averaging. *Journal of Econometrics*, **100**: 381–427.
- Fernández, C., Ley, E. y Steel, M. (2001b). Model uncertainty in cross-country growth regressions. *Journal of Applied Econometrics*, **16**: 563–576.
- Fernández, C., Osiewalski, J. y Steel, M. (1997). On the use of panel data in Bayesian stochastic frontier models. *Journal of Econometrics*, **79**: 169–193.
- Fieller, E. (1954). Some problems in interval estimation (with discussion). *Journal of the Royal Statistical Society, Series B*, **16**: 175–188.
- Foster, E. (1980). *Análisis Coste Beneficio*. Instituto de Estudios Fiscales, Madrid.

- Frame, P., Fryback, D. y Patterson, C. (1993). Screening for abdominal Aortic Aneurysm in men ages 60 to 80 years. A cost-effectiveness analysis. *Annals of Internal Medicine*, **119**: 411–416.
- Freedman, L. y Spiegelhalter, D. (1983). The assessment of subjective opinion and its use in relation to stopping rules for clinical trial. *The Statistician*, **33**: 153–160.
- Fryback, D., Chinnis, J. y Ulvila, J. (2001). Bayesian cost-effectiveness analysis. An example using the GUSTO trial. *International Journal of Technology Assessment in Health Care*, **17**: 83–97.
- Gail, M., Wieand, S. y Pianados, S. (1984). Biased estimates of treatment effect in randomized experiments with nonlinear regressions and omitted covariates. *Biometrika*, **71**: 431–444.
- Garber, A. y Phelps, C. (1995). *Economic Foundations of Cost-Effectiveness Analysis*. National Bureau of Economic Research.
- Garber, A., Weinstein, G., Torrance, G. y Kamlet, M. (1996). Theoretical Foundations of Cost-Effectiveness Analysis. M. Gold, J. Siegel, L. Russell y M. Weinstein, eds., *Cost-Effectiveness in Health and Medicine*, pp. 25–53. Oxford University Press, New York.
- Garry, R., Fountain, J., Mason, S., Napp, V., Brown, J., Hawe, J., Clayton, R., Abbott, J., Phillips, G., Whittaker, M., Lilford, R. y Bridgman, S. (2004). The EVALUATE study: Two parallel randomised trials, one comparing Laparoscopic with abdominal Hysterectomy, the other comparing Laparoscopic with vaginal Hysterectomy. *British Medical Journal*, **328**: 129–133.
- Gelman, A., Carlin, J., Stern, H. y Rubin, D. (1995). *Bayesian Data Analysis*. Chapman and Hall, London.

- Geman, R. y Geman, D. (1984). Stochastic relaxation, Gibbs distributions and the Bayesian restoration of images. *IEEE Transactions on Pattern Analysis and Machine Intelligence*, **6**: 721–741.
- Genest, C., y Zidek, J. (1986). Combining probability distributions: A critique and an annotated bibliography (with discussion). *Statistics in Medicine*, **1**: 114–148.
- Gilks, W., Richardson, S. y Spiegelhalter, D. (1996). *Markov Chain Monte Carlo in Practice*. Chapman and Hall, London.
- Glasziou, P., Simes, R. y Gelber, R. (1990). Quality adjusted survival analysis. *Statistics in Medicine*, **9**: 1259–1276.
- Glick, H., Willke, R., Polsky, D., Llana, T., Alves, W., Kassell, N. y Schulman, K. (1998). Economic analysis of Tirilazad Mesylate for Aneurysmal Subarachnoid hemorrhage. *International Journal of Technology Assessment in Health Care*, **14**: 145–160.
- Goeree, R., O'Brien, B., Hunt, R., Blackhouse, G., Willan, A. y Watson, J. (1999). Economic evaluation of long term management strategies for erosive Oesophagitis. *Pharmacoeconomics*, **16**: 679–697.
- Gold, M., Siegel, J., Russell, L. y Weinstein, M. (1996). *Cost-Effectiveness in Health and Medicine*. Oxford University Press, New York.
- Goldstein, H. (1995). *Multilevel Statistical Models*. Edward Arnold, London.
- Goldstein, H., Browne, W. y Rasbash, J. (2002). Multilevel modelling of medical data. *Statistics in Medicine*, **15**: 3291–3315.
- Goodwin, J., Hunt, W., Humble, C., Key, C. y Samet, J. (1988). Cancer treatment protocols. Who gets chosen? *Archives of Internal Medicine*, **148**: 2258–2260.

- Gray, A., Raikou, M., McGuire, A., Fenn, P., Stevens, R., Cull, C., Stratton, I., Adler, A., Holman, R. y Turner, R. (2000). Cost effectiveness of an intensive Blood Glucose Control policy in patients with type 2 Diabetes: Economic analysis alongside randomised controlled trial—Ukpds 41. *British Medical Journal*, **320**: 1373–1378.
- Grieve, R., Nixon, R., Thompson, S. y Normand, C. (2004). Using multilevel models for assessing the variability of multinational resource use and cost data. *Health Economics*, en prensa.
- Griffiths, W., Carter, R. y O'Donnell, C. (2001). Including prior information in probit model estimation. Research paper n° 816, Department of Economics, University of Melbourne.
- Grimmett, G. y Stirzaker, D. (2001). *Probability and Random Processes, 3rd edn.* Oxford University Press, Oxford.
- Healey, A., Mirandola, M., Amaddeo, F., Bonizzato, P. y Tansella, M. (2000). Using health production functions to evaluate treatment effectiveness: An application to a community mental health service. *Health Economics*, **9**: 373–383.
- Heitjan, D. (1997). Bayesian inteim analysis of Phase II Cancer clinical trials. *Statistics in Medicine*, **16**: 1791–1802.
- Heitjan, D. (2000). Fieller's method and net health benefits. *Health Economics*, **9**: 327–335.
- Heitjan, D., Moskowitz, A. y William, W. (1999). Bayesian estimation of cost–effectiveness ratios from clinical trials. *Health Economics*, **8**: 191–201.

- Henry, D. (1992). Economics analysis as an aid to subsidisation decisions: The development of Australia's guidelines for pharmaceuticals. *Pharmacoeconomics*, **1**: 54–67.
- Hoch, J., Briggs, A. y Willan, R. (2002). Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost–effectiveness analysis. *Health Economics*, **11**: 415–430.
- Hoeting, J., Madigan, D., Raftery, A. y Volinsky, C. (1999). Bayesian model averaging: A tutorial. *Statistical Science*, **14**: 382–427.
- Hunter, C., Frelick, R., Feldman, A., Bavier, A., Dunlap, W., Ford, L., Henson, D., MacFarlane, D., Smart, C., Yancik, R. y Yates, J. (1987). Selection factors in clinical trials: Results from the community clinical oncology program physician's patient log. *Cancer Treatment Reports*, **71**: 559–565.
- Hwang, J., Tsauo, J. y Wang, J. (1996). Estimation of expected quality adjusted survival by cross–sectional survey. *Statistics in Medicine*, **15**: 93–102.
- Hyder, A., Rotllant, G. y Morrow, R. (1998). Measuring the burden of disease: Healthy life years. *American Journal of Public Health*, **88**: 196–202.
- Ibrahim, J., Chen, M. y Sinha, D. (2001). *Bayesian Survival Analysis*. Springer–Verlag, Berlin, Heidelberg, New York, London, Paris, Tokyo, Hong Kong.
- Johannesson, M., Jonsson, B., Kjekshus, J., Olsson, A., Pedersen, T. y Wedel, H. (1997). Cost effectiveness of Simvastatin treatment to lower Cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin survival study group. *New England Journal of Medicine*, **303**: 332–336.
- Jones, D. (1996). Bayesian approach to the economic evaluation of health care technologies. B. Spiker, ed., *Quality of Life and Phamaeconomics in Clinical Trials*, pp. 1189–1196. Lippincott–Raven, Philadelphia.

- Kadane, J. (1980). Predictive and structural methods for eliciting prior distributions. A. Zellner, ed., *Bayesian Analysis in Econometrics and Statistics*. North-Holland, Amsterdam.
- Kadane, J. y Wolfson, L. (1995). Priors for the design and analysis of clinical trials. M. Dekker, ed., *Bayesian Biostatistics*, pp. 157–186. Berry, D. and Stangl, D., New York.
- Kadane, J. y Wolfson, L. (1998). Experiences in elicitation. *Journal of the Royal Statistical Society, D (The Statistician)*, **47**: 3–19.
- Kamath, C., Kremers, H., Vanness, D., O’Fallen, W., Cabanela, R. y Gabriel, S. (2003). The cost-effectiveness of Acetaminophen, NSAIDS, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. *Value in Health*, **6**: 144.
- Kamlet, M. (1992). *The Comparative Benefits Modelling Project: A Framework for Cost-Utility Analysis of Government Health Care Programs*. Department of Health and Human Services, Public Health Service, Washington, DC: U.S.
- Kaplan, R. y Bush, J. (1982). Health-related quality of life measurement for evaluation research and policy analysis. *Health Psychology*, **1**: 61–80.
- Kass, R. y Raftery, A. (1995). Bayes factors. *Journal of the American Statistical Association*, **90**: 773–780.
- Kathleen, E., Miller, V., Ernst, C., Nishimura, K. y Merritt, R. (2002). Neonatal health care costs related to smoking during pregnancy. *Health Economics*, **11**: 193–206.
- Koop, G., Osiewalski, J. y Steel, M. (1994). Bayesian efficiency analysis with a flexible form: The AIM cost function. *Journal of Business and Economic Statistics*, **12**: 339–346.

- Koop, G., Osiewalski, J. y Steel, M. (1995). Posterior analysis of stochastic frontier models using Gibbs sampling. *Computational Statistics*, **10**: 353–373.
- Koop, G., Osiewalski, J. y Steel, M. (1997). Bayesian efficiency analysis through individual effects: Hospital cost frontiers. *Journal of Econometrics*, **76**: 77–105.
- Koop, G., Osiewalski, J. y Steel, M. (1999). The components of output growth: A stochastic frontier analysis. *Oxford Bulletin of Economics and Statistics*, **61**: 455–487.
- Koop, G., Osiewalski, J. y Steel, M. (2000). Measuring the sources of output growth in a panel of countries. *Journal of Business and Economic Statistics*, **18**: 284–299.
- Korthals-de Bos, I., Smidt, N., van Tulder, M., Rutten-van Molken, M., Ader, H., van der Windt, D., Assendelft, W. y Bouter, L. (2004). Cost effectiveness of interventions for lateral epicondylitis: Results from a randomised controlled trial in primary care. *Pharmacoeconomics*, **22**: 183–195.
- Kronborg, C., Andersen, K. y Kragh-Sorensen, P. (2000). Cost function estimation: The choice of a model to apply to dementia. *Health Economics*, **9**: 397–409.
- Laska, E., Meisner, M. y Siegel, C. (1997). Statistical inference for cost-effectiveness ratios. *Health Economics*, **6**: 229–242.
- Leamer, E. (1978). *Specification Searches*. Wiley, New York.
- Leyland, A. y Goldstein, H. (2001). *Multilevel Modelling of Health Statistics*. Willey, Chichester.
- Lin, D. (2000). Linear regression analysis of censored medical costs. *Biostatistics*, **1**: 35–47.

- Lin, D. (2003). Regression analysis of incomplete cost data. *Statistics in Medicine*, **22**: 1181–1200.
- Lin, D., Feuer, E., Etzioni, R. y Wax, Y. (1997). Estimating medical costs from incomplete follow-up data. *Biometrics*, **53**: 419–434.
- Lothgren, M. y Zethraeus, N. (2000). Definition, interpretation and calculation of cost-effectiveness acceptability curves. *Health Economics*, **9**: 623–630.
- Luce, B. y Brown, R. (1995). The use of technology assessment by hospitals, health maintenance organizations, and third party payers in the United States. *International Journal of Technology Assessment in Health Care*, **11**: 79–92.
- Lynd, L. y O'Brien, B. (2004). Taking calculated risks: Advances in risk—benefit evaluation using probabilistic simulation methods.
- Maddala, G. (1983). *Limited dependent and qualitative variables in Econometrics*. Cambridge University Press, New York.
- Manca, A., Rice, N., Sculpher, M. y Briggs, A. (2004). Assessing generalisability by location in trial-based cost-effectiveness analysis: The use of multilevel models. *Health Economics*, en prensa.
- Mandel, J., Bond, J., Church, T., Snover, D., Bradely, G., Schuman, L. y Ederer, F. (1993). Reducing mortality from Colorectal Cancer by screening for fecal occult blood. Minnesota Colon Cancer control study. *New England Journal of Medicine*, **328**: 1365–1371.
- Manning, W., Fryback, D. y Weinstein, M. (1996). Reflecting uncertainty in cost-effectiveness analysis. M. Gold, M. Siegel, L. Rusell y M. Westein, eds., *Cost-Effectiveness in Health and Medicine*, pp. 247–275. Oxford University Press, New York.

- Manning, W. y Mullahy, J. (2001). Estimating log models: To transform or not to transform? *Journal of Health Economics*, **20**: 461–469.
- McFadden, D. (1974). Conditional logit analysis of quantitative choice behaviour. P. Zarembka, ed., *Frontiers of Econometrics*, pp. 105–142. Academic Press, New York.
- McPherson, K., Wennberg, J., Hovind, O. y Clifford, P. (1982). Small area variations in the use of common surgical procedures: An international comparison of New England, England and Norway. *Journal of Applied Econometrics*, **307**: 1310–1313.
- Mehrez, A. y Gafni, A. (1989). Quality-adjusted life years, utility theory, and healthy-years equivalents. *Medical Decision Making*, **9**: 142–149.
- Menzin, J., Oster, G., Davies, L., Drummond, M., Greiner, W., Lucioni, C., Merot, J., Rossi, F., Schulenburg, M. y Souetre, E. (1996). A multinational economic evaluation of rhDNase in the treatment of Cystic Fibrosis. *International Journal of Technology Assessment in Health Care*, **12**: 52–61.
- Min, C. y Zellner, A. (1993). Bayesian and non-Bayesian methods for combining models and forecasts with applications to forecasting international growth rates. *Journal of Econometrics*, **56**: 89–118.
- Mishan, E. (1988). *Cost-Benefit Analysis*. Unwin Hyman, London.
- Mullahy, J. y Stinnett, A. (1998). Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. *Medical Decision Making*, **18**: S68–S80.
- Murphy, A. y Winkler, R. (1977). Reliability of subjective probability forecasts of precipitation and temperature. *Applied Statistics*, **26**: 41–47.

- Murray, C. y López, A. (1996). *The Global Burden of Disease*. World Health Organization, Harvard School of Public Health, World Bank, Génova.
- Murray, C. y López, A. (2000). Progress and directions in refining the global burden of disease approach: a response to Williams. *Health Economics*, **9**: 69–82.
- Murray, C., Salomon, J. y Mathers, C. (2000). A critical examination of summary measures of population health. *Bulletin of the World Health Organization*, **78**: 981–994.
- Murray, C., Salomon, J., Mathers, C. y López, A. (2002). *Summary Measures of Population Health: Concepts, Ethics, Measurement and Applications*. World Health Organization, Geneva.
- Negrín, M., Martel, M. y Vázquez-Polo, F. (2004a). Handling uncertainty in economic evaluation with clinical trial data. Universidad de Cantabria, Santander, International conference on distribution theory, order statistics and inference in Honor of Barry C. Arnold.
- Negrín, M., Pinilla, J. y Vázquez-Polo, F. (2004b). Bayesian efficiency of Mental Health Care: Evidence from Spain. London School of Economics, Londres, Fifth European Conference on Health Economics.
- Negrín, M. y Vázquez-Polo, F. (2004). Bayesian cost–effectiveness analysis with two measures of effectiveness: The cost–effectiveness acceptability plane. En evaluación en Health Economics.
- Nelder, J. y McCullagh, P. (1989). *Generalized Linear Models*. Chapman and Hall, New York.
- Neuhaus, J. (1998). Estimation efficiency with omitted covariates in generalized linear models. *Journal of the American Statistical Association*, **93**: 1124–1129.

- Neuhaus, J. y Jewel, N. (1993). A geometric approach to assess bias due to omitted covariates in generalized linear models. *Biometrika*, **80**: 807–816.
- O'Brien, B., Drummond, M., Labelle, R. y Willan, A. (1994). In search of power and significance: Issues in the design and analysis of stochastic cost effectiveness studies in health care. *Medical Care*, **32**: 150–163.
- O'Hagan, A. (1994). *Kendall's Advanced Theory of Statistics. Volume 2B: Bayesian Inference*. Edward Arnold, London.
- O'Hagan, A. (1995). Fractional Bayes factors for model comparison (with discussion). *Journal of the Royal Statistical Society, Series B*, **57**: 99–138.
- O'Hagan, A. y Luce, B. (2003). *A Primer on Bayesian Statistics in Health Economics and Outcomes Research*. Bayesian Initiative in Health Economics & Outcomes Research, Centre of Bayesian Statistics in Health Economics, Sheffield.
- O'Hagan, A. y Stevens, J. (2001a). Bayesian assessment of sample size for clinical trials of cost–effectiveness. *Medical Decision Making*, **21**: 219–230.
- O'Hagan, A. y Stevens, J. (2001b). A framework for cost–effectiveness analysis from clinical trial data. *Health Economics*, **10**: 303–315.
- O'Hagan, A. y Stevens, J. (2003). Assessing and comparing costs: How robust are the bootstrap and methods based on asymptotic normality? *Health Economics*, **12**: 33–49.
- O'Hagan, A. y Stevens, J. (2004). On estimators of medical costs with censored data. *Journal of Health Economics*, **23**: 615–625.
- O'Hagan, A., Stevens, J. y Montmartin, J. (2000). Inference for the cost–effectiveness acceptability curve and cost–effectiveness ratio. *Pharmacoeconomics*, **17**: 339–349.

- O'Hagan, A., Stevens, J. y Montmartin, J. (2001). Bayesian cost-effectiveness analysis from clinical trial data. *Statistics in Medicine*, **20**: 733–753.
- Oliva, J. (1999). La valoración de costes indirectos en economía de la salud. Tech. rep., Documento de trabajo 9917 de la Universidad Complutense de Madrid.
- O'Neill, C., Groom, L., Avery, A., Boot, D. y Thornhill, K. (2000). Age and proximity to death as predictors of GP Care Costs: Results from a study of nursing home patients. *Health Economics*, **9**: 733–738.
- Ontario Ministry of Health (1994). Ontario guidelines for economic analysis of pharmaceutical products.
- Osiewalski, J. y Steel, M. (1998). Numerical tools for the Bayesian analysis of stochastic frontier models. *Journal of Productivity Analysis*, **10**: 103–117.
- Parmigiani, G. (2002). *Modelling in Medical Decision Making: A Bayesian Approach (Statistics in Practice)*. Wiley, Chichester.
- Phelps, C. y Mooney, C. (1993). Variations in medical practice use, causes and consequences. R. Arnoud, R. Rich y W. White, eds., *Competitive Approaches to Health Care Reform*. The Urban Institute Press: Washington, DC.
- Pinilla, J., González, B., Barber, P. y Santana, Y. (2002). Smoking in young adolescents: an approach with multilevel discrete choice models. *Journal Epidemiology and Community Health*, **56**: 227–232.
- Pinto, J., López, C., Badía, X., Corna, A. y Benavides, A. (2000). Análisis coste-efectividad del tratamiento antirretroviral de gran actividad en pacientes infectados por el VIH asintomáticos. *Medicina Clínica*, **114**: 62–67.
- Polsky, D., Glick, H., Wilke, R. y Schulman, K. (1997). Confidence intervals for cost-effectiveness ratios: A comparison of four methods. *Health Economics*, **6**: 243–252.

- Puigdollers, E., Cots, F., Brugal, M., Torralba, L. y Domingo-Salvany, A. (2002). Programas de mantenimiento de metadona con servicios auxiliares: Un estudio de coste–efectividad. *Gaceta Sanitaria*, **17**: 123–130.
- Raftery, A., Madigan, D. y Hoeting, J. (1997). Bayesian model averaging for linear regression models. *Journal of the American Statistical Association*, **92**: 179–191.
- Raikou, K., Gray, A., Briggs, A., Stevens, R., Cull, C., McGuire, A., Fenn, P., Stratton, I., Holman, R., Turner, R. y Group, U. P. D. S. (1998). Cost effectiveness analysis of improved blood pressure control in Hypertensive patients with Type 2 Diabetes: UKPCS 40. *British Medical Journal*, **317**: 720–726.
- Raikou, M., Briggs, A., Gray, A. y McGuire, A. (2000). Centre–specific or average unit costs in multi–centre studies? Some theory and simulation. *Health Economics*, **9**: 191–198.
- Rice, N. y Jones, A. (1997). Multilevel models and health economics. *Health Economics*, **6**: 561–575.
- Rice, N. y Leyland, A. (1996). Multilevel models: Applications to health data. *Journal of Health Services Research and Policy*, **1**: 154–164.
- Richardson, G. y Manca, E. (2004). Calculation of quality adjusted life years in the published literature: A review of methodology and transparency. *Health Economics*, en prensa.
- Russell, L. y Sisk, J. (2000). Modelling age differences in cost–effectiveness analysis. A review of the literature. *International Journal of Technology Assessment in Health Care*, **16**: 1158–1167.

- Rutten-van Molken, P., van Doorslaer, E. y Till, M. (1998). Cost-effectiveness analysis of Formoterol versus Salmeterol in patients with asthma. *Pharmacoeconomics*, **14**: 671–684.
- Sarabia, J., Gómez-Déniz, E. y Vázquez-Polo, F. (2004). On the use of conditional specification models in claim count distributions: An application to Bonus–Malus systems. *ASTIN Bulletin*, en prensa.
- Savage, L. (1971). Elicitation of personal probabilities and expectations. *Journal of the American Statistical Association*, **66**: 783–801.
- Schulman, K., Glick, H., Buxton, M., Sculpher, M., Backhouse, M., Bell, L. y Eisenberg, J. (1996). The economic evaluation of the FIRST study: Design of a prospective analysis alongside a multinational phase III clinical trial. *Controlled Clinical Trials*, **17**: 304–315.
- Sculpher, M. y Manca, A. (2004). The cost-effectiveness of Laparoscopic-assisted Hysterectomy in comparison with standard Hysterectomy: The EVALUATE Trial. *British Medical Journal*, **328**: 134–139.
- Shen, L., Pulkstenis, E. y Hoseyni, H. (1999). Estimation of mean quality adjusted survival time. *Statistics in Medicine*, **18**: 1541–1554.
- Snijders, T. y Bosker, R. (1999). *Multilevel Analysis*. Sage, London.
- Sox, H., Blatt, M., Higgins, M. y Marton, K. (1988). *Medical Decision Making*. Butterworths, Boston.
- Spiegelhalter, D., Abrams, K. y Myles, J. (2004). *Bayesian Approaches to Clinical Trials and Health-Care Evaluation*. John Wiley & Sons, Ltd, Chichester, England.

- Spiegelhalter, D. y Feedman, L. (1986). A predictive approach to selecting the size of clinical trial based on subjective clinical opinion. *Statistics in Medicine*, **5**: 1–13.
- Spiegelhalter, D., Feedman, L. y Parmar, M. (1994). Bayesian approaches to randomized trials (with discussion). *Journal of the Royal Statistical Society, Series A*, **157**: 357–416.
- Spiegelhalter, D., Feedman, L. y Parmar, M. (1995). Bayesian approaches to randomized trials. D. Berry y D. Stangl, eds., *Bayesian Biostatistics*, pp. 67–108. Marcel Dekker, New York.
- Spiegelhalter, D., Myles, J., Jones, D. y Abrams, K. (2000a). Bayesian methods in health technology assessment: A review. *Health Technology Assessment*, pp. 1–130.
- Spiegelhalter, D., Thomas, A. y Best, N. (2000b). WinBUGS Version 1.3. User manual, Biostatistics Unit, Cambridge Medical Research Council.
- Stevens, J. y O'Hagan, A. (2001). Bayesian methods for cost–effectiveness analysis. *ISPO T News*, **7**: 303–315.
- Stevens, J., O'Hagan, A. y Miller, P. (2003). Case study in the Bayesian analysis of a cost–effectiveness trial in the evaluation of health care technologies: Depression. *Pharmaceutical Statistics*, **2**: 51–68.
- Stinnett, A. y Mullahy, J. (1998). Net health benefits: A new framework for the analysis of uncertainty in cost–effectiveness analysis. *Medical Decision Making*, **18**: S65–S80.
- Sudre, P., Breman, J., McFarland, D. y Koplan, J. (1992). Treatment of Chloroquineresistant Malaria in African children: A cost–effectiveness analysis. *International Journal of Epidemiology*, **21**: 146–154.

- Tambour, M. y Zethraeus, N. (1995). Bootstrap confidence intervals for cost-effectiveness ratios: Some simulation results. *Health Economics*, **4**: 373–381.
- Tambour, M., Zethraeus, N. y Johannesson, M. (1998). A note on confidence intervals in cost-effectiveness analysis. *International Journal of Technology Assessment in Health Care*, **14**: 467–471.
- Thompson, S. y Barber, J. (2000). How should cost data in pragmatic randomised trials be analysed? – Education and debate. *British Medical Journal*, **320**: 1197–1200.
- Torrance, G. (1976). Toward a utility theory foundation for health status index models. *Health Services Research*, **11**: 349–369.
- Torrance, G. (1986). Measurement of health state utilities for economic appraisal. A review. *Journal of Health Economics*, **5**: 1–30.
- Torrance, G. (1987). Utility approach to measuring health-related quality of life. *Journal of Chronic Disease*, **40**: 593–603.
- Torrance, G. (1995). Designing and conducting cost-utility analyses. B. Spilker, ed., *Quality of life and pharmacoeconomics in clinical trials*, pp. 1105–1111. Lippincott-Raven, Philadelphia.
- Torrance, G. y Feeny, D. (1989). Utilities and quality-adjusted life years. *International Journal of Technology Assessment in Health Care*, **5**: 559–575.
- Torrance, G., Thomas, W. y Sackett, D. (1972). A utility maximization model for evaluation of health care programs. *Health Services Research*, **7**: 118–133.
- Torrens, M., San, L., Martínez, A., Castillo, C., Domingo-Salvany, A. y Alonso, J. (1997). Use of Nottingham health profile for measuring health status of patients in Methadone maintenance treatment. *Addiction*, **92**: 707–716.

- Tweedie, R. (1998). Markov Chains: Structure and applications. Department of Statistics, Colorado State University.
- Van den Broeck, J., Koop, G., Osiewalski, J. y Steel, M. (1994). Stochastic frontier models: A Bayesian perspective. *Journal of Econometrics*, **61**: 273–303.
- Van Hout, B., Al, M., Gordon, G. y Rutten, F. (1994). Costs, effects and C/E-ratios alongside a clinical trial. *Health Economics*, **3**: 309–319.
- Vanness, D. y Kim, W. (2002). Bayesian estimation, simulation and uncertainty analysis: The cost-effectiveness of Ganciclovir Prophylaxis in liver transplantation. *Health Economics*, **11**: 551–566.
- Vázquez-Polo, F. y Negrín, M. (2004). Incorporating patients' characteristics in cost-effectiveness studies with clinical trial data. A flexible Bayesian approach. *Statistics and Operation Research Transaction*, **28**: 87–108.
- Vázquez-Polo, F., Negrín, M., Badía, X. y Roset, M. (2004a). Bayesian regression models for cost-effectiveness analysis. *European Journal of Health Economics*, en prensa.
- Vázquez-Polo, F., Negrín, M. y González, B. (2004b). Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. *Health Economics*, en prensa.
- Wakker, P. y Klaasen, M. (1995). Confidence intervals for cost-effectiveness ratios. *Health Economics*, **4**: 373–381.
- Weinstein, M. (1990). Principles of cost-effective resource allocation in health care organizations. *International Journal of Technology Assessment in Health Care*, **6**: 93–103.

- Weinstein, M., Fineberg, H., Frazier, A., Neuhauser, D., Neutra, R. y McNeil, B. (1980). *Clinical Decision Analysis*. W.B. Saunders, Philadelphia.
- Weinstein, M. y Stason, W. (1977). Foundations of cost–effectiveness analysis for health and medical practices. *New England Journal of Medicine*, **296**: 716–721.
- Wennberg, J. (1984). Dealing with medical practice variations: A proposal for action. *Health Affairs*, **3**: 6–32.
- Willan, A., Briggs, A. y Hoch, J. (2004a). Regression methods for covariate adjustment and subgroup analysis for non–censored cost–effectiveness data. *Health Economics*, **13**: 461–475.
- Willan, A., Chen, E., Cook, R. y Lin, D. (2003). Incremental net benefit in clinical trials with quality–adjusted survival. *Statistics in Medicine*, **22**: 353–362.
- Willan, A., Lin, D., Cook, R. y Chen, E. (2002). Using inverse–weighting in cost–effectiveness analysis with censored data. *Statistical Methods in Medical Research*, **11**: 539–551.
- Willan, A., Lin, D. y Manca, A. (2004b). Regression methods for cost–effectiveness analysis with censored data.
- Willan, A. y O’Brien, B. (1996). Confidence intervals for cost–effectiveness ratios: An application of Fieller’s theorem. *Health Economics*, **5**: 297–305.
- Willan, A. y O’Brien, B. (2001). Cost prediction models for the comparison of two groups. *Health Economics*, **10**: 363–366.
- Willard, K. y Critchfield, G. (1986). Probabilistic analysis of decision trees using symbolic algebra. *Medical Decision Making*, **6**: 93–100.

- Williams, A. (1999). Calculating the global burden of disease: Time for strategic reappraisal? *Health Economics*, **8**: 1–8.
- Willke, R., Glick, H., Polsky, D. y Schulman, K. (1998). Estimating country-specific cost-effectiveness from multinational clinical trials. *Health Economics*, **7**: 481–493.
- Winkler, R. (1967). The assessment of prior distributions in Bayesian analysis. *Journal of the American Statistical Association*, **63**: 776–800.
- Wolpert, R. (1989). Eliciting and combining subjective judgements about uncertainty. *International Journal of Technology Assessment in Health Care*, **5**: 537–557.
- Yates, B. (1979). Cost-effectiveness analysis of a residential treatment center for disturbed preadolescents. G. Landsberg, W. Neigher, R. Hammer, C. Windle y R. Woy, eds., *Evaluation in Practice: A Sourcebook of Program Evaluation Studies from Mental Health Care Systems in the United States*. National Institute of Mental Health, Washington, D.C.
- Yates, B., Lockwood, D., Saylor, K., Andrews, M., Shiraki, S., Delany, P., Bestamen, K., Heath, J., Inciardi, J., Merrill, J., Myers, J. y Zarkin, G. (1999). *Measuring and Improving Cost, Cost-Effectiveness and Cost-Benefit for Substance Abuse Treatment Programs*. National Institutes of Health, U.S.
- Zhao, H. y Tian, L. (2001). On estimating medical cost and incremental cost-effectiveness ratios with censored data. *Biometrics*, **57**: 1002–1008.
- Zhao, H. y Tsiatis, A. (1997). A consistent estimator for the distribution of quality adjusted survival time. *Biometrika*, **84**: 339–348.
- Zhao, H. y Tsiatis, A. (1999). Efficient estimation of the distribution of quality adjusted survival time. *Biometrics*, **55**: 1101–1107.